Phase II study of cystemustine in metastatic colorectal carcinoma. A trial of the EORTC Clinical Screening Group.

European journal of cancer (Oxford, England : 1990)

PubMedID: 8217367

Kerbrat P, Adenis A, Rebattu P, Roche H, Chevallier B, Chollet P, Krakowski I, Lentz MA, Fumoleau P. Phase II study of cystemustine in metastatic colorectal carcinoma. A trial of the EORTC Clinical Screening Group. Eur J Cancer. 1993;29A(11):1597-9.
27 patients with metastatic colorectal carcinoma were treated, every 2 weeks, with 60 mg/m2 cystemustine, a new chloro-2-ethyl nitrosourea derivative. Haematological toxicity was the major side-effect including neutropenia and thrombocytopenia. We did not observe any complete or partial response. Cystemustine, with this dose and this schedule, has no activity in colorectal cancer.